Inventiva (IVA) Liabilities and Shareholders Equity (2018 - 2025)

Inventiva's (IVA) quarterly Liabilities and Shareholders Equity came in at $290.4 million in Q4 2025, up 128.46% year-on-year from $127.1 million in Q4 2024, and down 99.86% quarter-over-quarter from $202.6 billion in Q2 2025.

Inventiva (IVA) Liabilities and Shareholders Equity (2018 - 2025) Analysis & Trends

Inventiva's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $290.4 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 128.46% year-over-year to $290.4 million in Q4 2025; TTM through Dec 2025 was $203.0 billion, a 78694.75% increase from a year earlier, with the FY2025 full-year figure at $290.4 million, up 128.46% from the prior year.
  • Liabilities and Shareholders Equity eased to $290.4 million in Q4 2025 per IVA's latest filing, from $202.6 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $202.6 billion in Q2 2025 and bottomed at $115662.5 in Q2 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $127.1 million (2024), against an average of $18.5 billion.
  • Across the five-year window, Liabilities and Shareholders Equity plunged 99.92% in 2022 and jumped 977941.76% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $139.5 million in 2021, then slipped by 15.19% to $118.4 million in 2022, then slumped by 36.76% to $74.8 million in 2023, then soared by 69.86% to $127.1 million in 2024, then jumped by 128.46% to $290.4 million in 2025.
  • Per Business Quant, the three latest IVA Liabilities and Shareholders Equity figures stand at $290.4 million (Q4 2025), $202.6 billion (Q2 2025), and $127.1 million (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Inventiva 842.48 Mn 842.48 Mn - 290.44 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 290.44 Mn
Jun 30, 2025 202.57 Bn
Dec 31, 2024 127.13 Mn
Jun 30, 2024 20.71 Mn
Dec 31, 2023 74.84 Mn
Oct 11, 2023 34.96 Mn
Dec 31, 2022 118.35 Mn
Jun 30, 2022 115,662.54
Dec 31, 2021 139.55 Mn
Jun 30, 2021 141.16 Mn
Mar 31, 2021 159.49 Mn
Dec 31, 2020 165.63 Mn
Jun 30, 2020 75.70 Mn
Dec 31, 2019 63.05 Mn
Dec 31, 2018 91.10 Mn